As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner.
COL18A1 Marker
Collagen alpha-1(XVIII) chain (COL18A1) is a collagen protein that in human is encoded by the COL18A1 gene. The type XVIII collagen is one of the multiplexins, extracellular matrix proteins which comprise multiple triple-helix domains (collagenous domains) barged by non-collagenous domains. COL18A1 protein is primarily expressed by hepatocytes of normal, cirrhotic and neoplastic liver. A long isoform of the collagen alpha-1(XVIII) chain has an N-terminal domain that is homologous to the extracellular part of frizzled receptors. Proteolytic processing at several endogenous cleavage sites in the C-terminal domain lead to production of endostatin, a potent antiangiogenic protein that can inhibit angiogenesis and tumor growth. COL18A1 protein may inhibit angiogenesis through binding to the heparan sulfate proteoglycans which are involved in growth factor signaling (via the similarity). COL18A1 protein also can inhibit VEGFA-mediated signaling and suppress VEGFA-induced endothelial cell proliferation and migration, probably via blocking the interaction of VEGFA to its receptor KDR/VEGFR2.
Fig.1 Schematic picture of the structure of collagen alpha-1(XVIII).1
The Role of COL18A1 in Ovarian Cancer
Studies represent that a COOH-terminal fragment of the COL18A1 protein corresponds to the antiangiogenic factor endostatin, and overexpression of endostatin has been associated with ovarian cancer. COL18A1 overexpression is regarded as a promising biomarker for ovarian cancer, due to the central involvement of endostatin in angiogenesis and its function in tumor growth. The proteolytically produced C-terminal fragment of COL18A1 protein is endostatin, which can bind to ovarian cancer cells and suppress peritoneal attachment and dissemination. It has been demonstrated that transcription levels of VEGF and endostatin may be an assistant method to cytology screening for early detection of cervical carcinomas. COL18A1 RNA is highly expressed in both carcinoma and stromal cells in ovarian cancer. And stimulation of proteolysis of the locally highly expressed COL18A1 to endostatin may provide a potential approach for a targeted antineoplastic therapy.
Ovarian cancer is a serious malignancy with high mortality because of difficulties in detection, diagnosis, and treatment. As IVD antibodies present great potential for disease diagnosis, Creative Biolabs has built a novel platform for IVD antibody development against the COL18A1 marker. Our services can be tailor-designed to meet our customers’ specific requirements.
In addition, Creative Biolabs provides one-stop diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, validation, and production. If you are interested in our services, please feel free to contact us for more information.
Reference
For Research Use Only.
